41
Participants
Start Date
November 1, 2018
Primary Completion Date
August 12, 2022
Study Completion Date
October 18, 2024
axatilimab
axatilimab is a high affinity antibody targeting the colony stimulating factor 1 receptor (CSF-1R). CSF-1R signaling has been demonstrated in nonclinical studies to be the key regulatory pathway involved in the expansion and infiltration of donor derived macrophages that mediate the disease processes involved in cGVHD.
University of Miami Miller School of Medicine, Miami
University of Alabama at Birmingham, Birmingham
Indiana University Health Melvin and Bren Simon Cancer Center, Indianapolis
Karmanos Cancer Institute, Detroit
University of Minnesota Medical Center, Minneapolis
Washington University School of Medicine, St Louis
University of Utah Health Huntsman Cancer Institute, Salt Lake City
City of Hope, Duarte
Fred Hutchinson Cancer Research Center, Seattle
Massachusetts General Hospital, Boston
Vanderbilt-Ingram Cancer Center, Nashville
Lead Sponsor
Syndax Pharmaceuticals
INDUSTRY